Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Completed 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 14Breast 7Myeloid 6Thoracic 5Gynecologic 3Genitourinary 3Dermatologic 3Classical hematology 3Plasma cell 2Head & Neck 2CNS 2Tumor-Agnostic 1Other neoplasm 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Tobacco Use Disorder 1Smoking Cessation 1Motor Activity 1Inflammation 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Aspirin × Thoracic × Clear all
NCT03654105 2026-03-27

SMILE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Active not recruiting
2,000 enrolled
Thoracic

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Completed
216 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03543683 2025-02-27

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Completed
115 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06018688 2023-09-21

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Not yet recruiting
44 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02123849 2018-08-29

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

National Cancer Institute (NCI)

Phase 2 Completed
54 enrolled 15 charts
Thoracic

Lung Neoplasms, Tobacco Use Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡